The rise in antibiotic resistance in gonorrhea isolates following the endorsement of using the antibiotic doxycycline for post-exposure prophylaxis (PEP) is a concerning development. A recent study published in the New England Journal of Medicine reported a significant increase in resistance to tetracycline, the antibiotic class to which doxycycline belongs, in gonorrhea isolates collected nationwide. This rise in resistance was also observed in other bacterial pathogens carried by individuals who took doxy PEP.
Yonatan Grad, the senior author of the study, emphasized the benefits of using doxy PEP for controlling STIs like chlamydia and syphilis, as well as reducing rates of congenital syphilis. However, the study highlighted the cost of this approach, which is the increasing resistance in other bacterial pathogens. This evidence indicates that the theoretical concern of antibiotic resistance driving by doxy PEP is now a reality.
Several studies have shown the effectiveness of using a single dose of doxycycline within 72 hours of unprotected sex in reducing STI rates. However, the rise in antibiotic resistance poses a significant challenge to this approach. While countries like the United States, Germany, and Australia have adopted the use of doxy PEP, others are cautious or discourage its use due to concerns about antibiotic stewardship.
Gonorrhea is known for its ability to develop resistance to antibiotics over time. Currently, ceftriaxone is the recommended first-line treatment for gonorrhea, and resistance to tetracycline does not impact its effectiveness. However, there are already strains of gonorrhea resistant to ceftriaxone, mainly circulating in Asia. The development of new antibiotics for gonorrhea treatment is underway, but the concern remains about the potential for future resistance.
Experts not involved in the study expressed their lack of surprise at the findings, highlighting the ongoing challenge of antibiotic resistance in the context of STI treatment. The study underscores the importance of balancing the benefits of PEP with the potential risks of driving antibiotic resistance in other bacterial infections. Efforts to address this issue through continued research and surveillance are crucial to safeguarding the effectiveness of antibiotics in combating STIs. The importance of monitoring the evolving resistance patterns in gonorrhea has been underscored by recent findings, according to Barbara Van Der Pol, a professor of medicine and public health at the University of Alabama at Birmingham. Van Der Pol emphasized the need for ongoing surveillance of Neisseria gonorrhoeae for public health purposes.
Jeanne Marrazzo, an expert in sexually transmitted infections (STIs), raised concerns about the temporary closure of the CDC laboratory responsible for surveillance and testing of gonorrhea resistance patterns. Marrazzo, who previously served as the director of the National Institute of Allergy and Infectious Diseases, warned that without adequate resources for analysis, crucial data may be compromised.
Despite the findings, Marrazzo does not believe it is time to reconsider the use of doxycycline post-exposure prophylaxis (PEP). However, she suggested that the benefits of doxy PEP may be temporary and that a more sustainable solution would be the development of an effective vaccine for gonorrhea.
Dr. Grad, another expert in the field, acknowledged the challenges of discontinuing the use of doxy PEP, as at-risk populations have already adopted this practice, even in the absence of formal endorsements from public health authorities. A recent study in the Netherlands revealed that a significant portion of individuals had used doxy PEP informally, indicating a strong intention to continue its use.
Despite the difficulty in halting the use of doxy PEP, Grad emphasized the clinical benefits of this practice in reducing rates of syphilis and chlamydia. The ongoing discussion surrounding the use of doxy PEP highlights the complex nature of STI prevention and the importance of ongoing research and surveillance in combating antibiotic resistance in gonorrhea.
In conclusion, the need for continued monitoring of gonorrhea resistance patterns and the development of sustainable prevention strategies remains a top priority in the field of public health. The findings discussed by Van Der Pol, Marrazzo, and Grad underscore the importance of vigilance and collaboration in addressing the challenges posed by antibiotic resistance in STIs.
